Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
8.14
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Cullinan Therapeutics stock have an average target of 32.86, with a low estimate of 26 and a high estimate of 40. The average target predicts an increase of 303.69% from the current stock price of 8.14.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +305.41% | Apr 16, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $38 → $35 | Buy | Initiates | $38 → $35 | +329.98% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +305.41% | Feb 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $28 → $33 | Strong Buy | Maintains | $28 → $33 | +305.41% | Jan 29, 2025 |
| UBS | UBS | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +268.55% | Oct 24, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
33.40M
EPS This Year
-3.36
from -3.11
EPS Next Year
-3.01
from -3.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 84.0M | 251.8M | ||
| Avg | n/a | 33.4M | 48.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 654.0% | ||
| Avg | - | - | 45.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.02 | -2.39 | -2.00 | ||
| Avg | -3.36 | -3.01 | -3.25 | ||
| Low | -3.61 | -3.89 | -4.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.